On-Demand Oral Pre-exposure Prophylaxis with Tenofovir/Emtricitabine: What Every Clinician Needs to Know

Parya Saberi, Hyman M Scott, Parya Saberi, Hyman M Scott

Abstract

Based on the results of the IPERGAY study, on-demand HIV pre-exposure prophylaxis (PrEP; also known as "non-daily PrEP," "event-driven PrEP," or "2-1-1 PrEP") is being requested more frequently by patients who have intermittent sexual risk or are unable/unwilling to take daily PrEP; therefore, clinicians will be increasingly required to familiarize themselves with its appropriate use. In this perspective, we summarize data related to on-demand PrEP, describe advantages and disadvantages for this alternative dosing strategy, and provide clinical counseling points.

Keywords: 2-1-1; PrEP; clinician; on-demand; pre-exposure prophylaxis; tenofovir/emtricitabine.

Conflict of interest statement

The authors declare that they do not have a conflict of interest.

Figures

Figure 1
Figure 1
Examples for the use of on-demand PrEP. Note refers to “sex day.”

References

    1. Molina JM, Capitant C, Spire B, et al. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. New Engl J Med. 2015;373(23):2237–2246. doi: 10.1056/NEJMoa1506273.
    1. Molina JM, Charreau I, Spire B, et al. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet Hiv. 2017;4(9):E402–E410. doi: 10.1016/S2352-3018(17)30089-9.
    1. Anderson PL, Glidden DV, Liu A, et al. Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men. Sci Transl Med. 2012;4(151).
    1. Grant RM, Lama JR, Anderson PL, et al. Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. New Engl J Med. 2010;363(27):2587–2599. doi: 10.1056/NEJMoa1011205.
    1. Saag MS, Benson CA, Gandhi RT, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2018;320(4):379–396. doi: 10.1001/jama.2018.8431.
    1. Fauci A. Ending the HIV Epidemic: a plan for the united states (Abstract #2010). Conference on Retroviruses and Opportunistic Infections (CROI); 2019.
    1. Marcus JL, Levine K, Grasso C, et al. HIV Preexposure Prophylaxis as a Gateway to Primary Care. Am J Public Health. 2018;108(10):1418–1420. doi: 10.2105/AJPH.2018.304561.
    1. Whitfield THF, Jones SS, Wachman M, Grov C, Parsons JT, Rendina HJ. The Impact of Pre-Exposure Prophylaxis (PrEP) Use on Sexual Anxiety, Satisfaction, and Esteem Among Gay and Bisexual Men. J Sex Res. 2019:1–8.
    1. Mabire X, Puppo C, Morel S, et al. Pleasure and PrEP: Pleasure-Seeking Plays a Role in Prevention Choices and Could Lead to PrEP Initiation. Am J Mens Health. 2019;13(1).
    1. Calabrese SK, Earnshaw VA, Underhill K, Hansen NB, Dovidio JF. The impact of patient race on clinical decisions related to prescribing HIV pre-exposure prophylaxis (PrEP): assumptions about sexual risk compensation and implications for access. Aids Behav. 2014;18(2):226–240. doi: 10.1007/s10461-013-0675-x.
    1. Calabrese SK, Krakower DS, Mayer KH. Integrating HIV Preexposure Prophylaxis (PrEP) Into Routine Preventive Health Care to Avoid Exacerbating Disparities. Am J Public Health. 2017;107(12):1883–1889. doi: 10.2105/AJPH.2017.304061.
    1. Siegler AJ, Mouhanna F, Giler RM, et al. The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States. Ann Epidemiol. 2018;28(12):841–849. doi: 10.1016/j.annepidem.2018.06.005.
    1. Finlayson T, Cha SS, Xia M, et al. Changes in HIV Preexposure Prophylaxis Awareness and Use Among Men Who Have Sex with Men-20 Urban Areas, 2014 and 2017. Mmwr-Morbid Mortal W. 2019;68(27):597–603. doi: 10.15585/mmwr.mm6827a1.
    1. Huang YLA, Zhu WM, Smith DK, Harris N, Hoover KW. HIV Preexposure Prophylaxis, by Race and Ethnicity - United States, 2014-2016. Mmwr-Morbid Mortal W. 2018;67(41):1147–1150. doi: 10.15585/mmwr.mm6741a3.
    1. Auerbach JD, Hoppe TA. Beyond "getting drugs into bodies": social science perspectives on pre-exposure prophylaxis for HIV. J Int Aids Soc. 2015;18(4 Suppl 3):19983. doi: 10.7448/IAS.18.4.19983.
    1. Zimmermann HM, Eekman SW, Achterbergh RC, et al. Motives for choosing, switching and stopping daily or event-driven pre-exposure prophylaxis - a qualitative analysis. J Int Aids Soc. 2019;22(10):e25389. doi: 10.1002/jia2.25389.
    1. Durand-Zaleski I, Mutuon P, Charreau I, et al. Costs and benefits of on-demand HIV preexposure prophylaxis in MSM. Aids. 2018;32(1):95–102. doi: 10.1097/QAD.0000000000001658.
    1. Liegeon G, Antoni G, Pialoux G, et al. Changes in kidney function among MSM initiating on-demand TDF/FTC for HIV PrEP (Abstract #960). Paper presented at: Conference on Retrovirusis and Opportunistic Infections2019; Seattle, WA.
    1. Rodriguez-Novoa S, Labarga P, D'Avolio A, et al. Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. Aids. 2010;24(7):1064–1066. doi: 10.1097/QAD.0b013e32833202e2.
    1. Anderson PL, Garcia-Lerma JG, Heneine W. Nondaily preexposure prophylaxis for HIV prevention. Current opinion in HIV and AIDS. 2016;11(1):94–101. doi: 10.1097/COH.0000000000000213.
    1. Volk JE, Liu A, Vittinghoff E, et al. Sexual Frequency and Planning Among At-Risk Men Who Have Sex With Men in the United States: Implications for Event-Based Intermittent Pre-Exposure Prophylaxis. Jaids-J Acq Imm Def. 2012;61(1):112–115. doi: 10.1097/QAI.0b013e31825bd87d.
    1. Kibengo FM, Ruzagira E, Katende D, et al. Safety, Adherence and Acceptability of Intermittent Tenofovir/Emtricitabine as HIV Pre-Exposure Prophylaxis (PrEP) among HIV-Uninfected Ugandan Volunteers Living in HIV-Serodiscordant Relationships: A Randomized, Clinical Trial. Plos One. 2013;8(9).
    1. Hiransuthikul A., Himmad K., Kerr S, et al. Drug-drug interactions between the use of feminizing hormone therapy and pre-exposure prophylaxis among transgender women: The iFACT study. Paper presented at: AIDS 20182018; Amsterdam, The Netherlands.
    1. Fung J, Lai CL, Yuen MF. Management of chronic hepatitis B in severe liver disease. World J Gastroenterol. 2014;20(43):16053–16061. doi: 10.3748/wjg.v20.i43.16053.
    1. Di Ciaccio M, Protiere C, Castro DR, et al. The ANRS-Ipergay trial, an opportunity to use qualitative research to understand the perception of the "participant"-physician relationship. Aids Care. 2018;30:41–47. doi: 10.1080/09540121.2018.1468013.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner